Double-blind, placebo-controlled comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease

Alimentary Pharmacology and Therapeutics

Volumn 13, Issue 1, 1999, Pages 49-57

  Dekkers, C P M ^a   Beker, J A ^b   Thjodleifsson, B ^c   Gabryelewicz, A ^e   Bell, N E ^d   Humphries, T J ^d  

^a Ignatius Hospital   (Netherlands)

^b MEDICAL CENTER HAAGLANDEN   (Netherlands)

^c LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^d EISAI CO LTD   (Japan)

^e Hammersmith International Centre ^*

Author keywords

[No Author keywords available]

Indexed keywords

GASTRIN; OMEPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; 2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE; ANTIULCER AGENT; BENZIMIDAZOLE DERIVATIVE; PROTON PUMP;

ADULT; AGED; ARGYROPHILIA; ARTICLE; ASTHENIA; ATROPHY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIGESTIVE TRACT ENDOSCOPY; DOUBLE BLIND PROCEDURE; FEMALE; FLATULENCE; FLU LIKE SYNDROME; GASTRIN BLOOD LEVEL; GASTROENTERITIS; GASTROESOPHAGEAL REFLUX; GRAM NEGATIVE INFECTION; HEADACHE; HEARTBURN; HELICOBACTER PYLORI; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPERPLASIA; HYPERTENSION; INFLAMMATION; INTESTINE METAPLASIA; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SOMNOLENCE; STOMACH ANTRUM; STOMACH BIOPSY; STOMACH EROSION; STOMACH MUCOSA; STOMACH ULCER; ULCER HEALING; URINALYSIS; COMPARATIVE STUDY; DRUG ANTAGONISM; EUROPE; GASTROINTESTINAL ENDOSCOPY; MIDDLE AGED; PEPTIC ULCER; TREATMENT OUTCOME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGED; AGED, 80 AND OVER; ANTI-ULCER AGENTS; BENZIMIDAZOLES; DOUBLE-BLIND METHOD; ENDOSCOPY, GASTROINTESTINAL; EUROPE; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PEPTIC ULCER; PROTON PUMPS; TREATMENT OUTCOME;

EID: 0032915278     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1999.00438.x     Document Type: Article

References (21)

1. 1 Kovacs TOG, Sytnik B, Humphries TJ, Walsh JH. A low dose of a new proton pump inhibitor LY307640 (E3810) effectively inhibits acid secretion in humans. Gastroenterology 1996; 110: A161(Abstract).
2. 2 Blanshard C, Millson C, Sercombe J, Pounder RE. The effects of rabeprazole on 24-hour intragastric acidity and plasma gastrin concentration in healthy subjects. Gut 1996; 39(Suppl. 3): A47(Abstract).
3. + activity and nocturnal acid secretion in healthy subjects. Gut 1996; 39(Suppl. 3): A47(Abstract).
4. 4 Sabesin SM, Berlin RG, Humphries TJ, et al. Famotidine relieves symptoms of gastroesophageal reflux disease and heals erosions and ulcerations. Results of a multicenter, placebo-controlled, dose-ranging study. Arch Intern Med 1991; 151: 2394-400.
5. 5 Wesdorp ICE, Dekker W, Festen HPM. Efficacy of famotidine 20 mg twice a day versus 40 mg twice a day in the treatment of erosive or ulcerative reflux oesophagitis. Dig Dis Sci 1993; 38: 2287-92.
6. 6 Cloud ML, Enas N, Humphries TJ. Rabeprazole in treatment of acid peptic diseases: Results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer and gastroesophageal reflux disease (GERD). Dig Dis Sci 1998; 43: 993-1000.
7. 7 Humphries TJ, Nardi RV, Lazar JD, Spanyers SA. Drug-drug interaction evaluation of rabeprazole sodium: a clean/expected slate? Gut 1996; 39(Suppl. 3): A47(Abstract).
8. 8 Wilde MI, McTavish D. Omeprazole: an update of its pharmacology and therapeutic use in acid-related disorders. Drugs 1994; 48: 91-132.
9. 9 Hetzel DJ, Dent J, Reed WD, Narielvala FM, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroentcrology 1988; 95: 903-12.
10. 10 Donner A. Approaches to sample size estimation in the design of clinical trials - a review. Stat Med 1984; 3: 199-214.
11. 11 Casagrande JP, Pike MC, Smith PG. An improved approximate formula for calculating sample sizes for comparing two binomial distributions. Biometric 1978; 34(3): 483-6.
12. 12 Feldman M, Burton ME. Histamine 2-receptor antagonists: standard therapy for acid diseases. N Engl J Med 1990; 323: 1749-55.
13. 13 Collen MJ, Lewis JH, Benjamin SB. Gastric acid hypersecretion in refractory gastro-oesophageal reflux disease. Gastroenterology 1990; 98: 654-61.
14. 14 Hunt RH. The relationship between the control of pH and healing and symptom relief in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1995; 9(Suppl. 1): 3-7.
15. 15 Robinson M, Maton PN, Rodriguez S, Greenwood B, Humphries TJ. Effects of oral rabeprazole on oesophageal and gastric pH in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1997; 4: 973-80.
16. 16 McTavish D, Buckley MMT, Heel RC. Omeprazole: an updated review of its pharmacology and therapeutic use in acid-related disorders. Drugs 1991; 42: 138-70.
17. 17 Mee AS, Rowley JL & the Lansoprazole Clinical Research Group. Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole. Aliment Pharmacol Ther 1996; 10: 757-63.
18. 18 Castell DO, Richter JE, Robinson M, Sontag SJ, Haber MM & the Lansoprazole Group. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. Am J Gastroenterol 1996; 91: 1749-57.
19. 19 Earnest DL, Dorsch E, Jones J, Jennings DE, Greski-Rose PA. A placebo-controlled dose-ranging study of lansoprazole in the management of reflux esophagitis. Am J Gastroenterol 1998; 93: 238-43.
20. 20 Mossner J, Holscher AH, Herz R, Schneiders A. A double-blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis: a multicentre trial. Aliment Pharmacol Ther 1995; 9: 321-6.
21. 21 Corinaldesi R, Valentini M, Belaiche J, Colin R, Geldof H, Maier C & the European Pantoprazole Study Group. Pantoprazole and omeprazole in the treatment of reflux oesophagitis: a European multicentre study. Aliment Pharmacol Ther 1995; 9: 667-71.